RAGE Isoforms, its Ligands and their Role in Pathophysiology of Alzheimer’s Disease

doi:10.2174/1567205018666210218164246
摘要

先进糖基化终产物（RAGE）的受体由于能够结合各种配体，因此在多种生理和病理过程中起着至关重要的作用。还存在多种形式的RAGE。一些在促进前馈途径方面的工作，而另一些则在发挥抑制作用。这篇综述集中在RAGE同工型表达，其通过RAGE-配体相互作用的细胞内途径激活及其在脑的生理和病理过程中的重要性。许多研究表明，RAGE是炎症的介体和氧化应激的诱导剂，可诱导阿尔茨海默病（AD）的病理生理变化。 RAGE在AD中的关键作用包括其参与淀粉样β（Aβ）的产生，清除，突触损伤和神经元回路功能障碍。 RAGE-Aβ相互作用还介导外围系统和中央系统之间的双向串扰。这种相互作用是破坏大脑物质结构和生理的潜在分子途径的基础。这篇综述强调了RAGEAβ相互作用的结构-功能关系，以及RAGE作为AD治疗发展中潜在靶点的作用。
关键词: 晚期糖基化终产物的受体，RAGE亚型，配体，淀粉样β蛋白，炎症，阿尔茨海默氏病，活性氧，治疗靶标。
« Previous Next »
[1] 
Lee EJ, Park JH. Receptor for advanced glycation end products (RAGE), its ligands, and soluble RAGE: Potential biomarkers for diagnosis and therapeutic targets for human renal diseases. Genomics Inform  2013; 11(4): 224-9.
[http://dx.doi.org/10.5808/GI.2013.11.4.224] [PMID:  24465234] 
[2] 
Stern D, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts: A multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev  2002; 54(12): 1615-25.
[http://dx.doi.org/10.1016/S0169-409X(02)00160-6] [PMID:  12453678] 
[3] 
Piras S, Furfaro AL, Domenicotti C, et al. RAGE expression and ROS generation in neurons: differentiation versus damage. Oxid Med Cell Longev  2016; 20169348651
[http://dx.doi.org/10.1155/2016/9348651] [PMID:  27313835] 
[4] 
Ott C, Jacobs K, Haucke E, et al. Role of advanced glycation end products in cellular signaling. Redox Biol  2014; 2: 411-29.
[http://dx.doi.org/10.1016/j.redox.2013.12.016] [PMID:  24624331] 
[5] 
Choi BR, Cho WH, Kim J, et al. Increased expression of the receptor for advanced glycation end products in neurons and astrocytes in a triple transgenic mouse model of Alzheimer’s disease. Exp Mol Med  2014; 46(2)e75
[http://dx.doi.org/10.1038/emm.2013.147] [PMID:  24503708] 
[6] 
Sochocka M, Diniz BS, Leszek J. Inflammatory response in the CNS: Friend or foe? Mol Neurobiol  2017; 54(10): 8071-89.
[http://dx.doi.org/10.1007/s12035-016-0297-1] [PMID:  27889895] 
[7] 
Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetes. Cardiovasc Res  2004; 63(4): 582-92.
[http://dx.doi.org/10.1016/j.cardiores.2004.05.001] [PMID:  15306213] 
[8] 
Scivittaro V, Ganz MB, Weiss MF. AGEs induce oxidative stress and activate protein kinase C-β(II) in neonatal mesangial cells. Am J Physiol Renal Physiol  2000; 278(4): F676-83.
[http://dx.doi.org/10.1152/ajprenal.2000.278.4.F676] [PMID:  10751230] 
[9] 
Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab  2001; 280(5): E685-94.
[http://dx.doi.org/10.1152/ajpendo.2001.280.5.E685] [PMID:  11287350] 
[10] 
Basta G, Lazzerini G, Massaro M, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: A mechanism for amplification of inflammatory responses. Circulation  2002; 105(7): 816-22.
[http://dx.doi.org/10.1161/hc0702.104183] [PMID:  11854121] 
[11] 
Hudson BI, Kalea AZ, Del Mar Arriero M, et al. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem  2008; 283(49): 34457-68.
[http://dx.doi.org/10.1074/jbc.M801465200] [PMID:  18922799] 
[12] 
Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J  2003; 370(Pt 3): 1097-109.
[http://dx.doi.org/10.1042/bj20021371] [PMID:  12495433] 
[13] 
Bowler E, Oltean S. Alternative splicing in angiogenesis. Int J Mol Sci  2019; 20(9): 2067.
[http://dx.doi.org/10.3390/ijms20092067] [PMID:  31027366] 
[14] 
Ding Q, Keller JN. Evaluation of rage isoforms, ligands, and signaling in the brain. Biochim Biophys Acta  2005; 1746(1): 18-27.
[http://dx.doi.org/10.1016/j.bbamcr.2005.08.006] [PMID:  16214242] 
[15] 
Ding Y, Kantarci A, Hasturk H, Trackman PC, Malabanan A, Van Dyke TE. Activation of RAGE induces elevated O2- generation by mononuclear phagocytes in diabetes. J Leukoc Biol  2007; 81(2): 520-7.
[http://dx.doi.org/10.1189/jlb.0406262] [PMID:  17095613] 
[16] 
Yan SD, Chen X, Fu J, et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer’s disease. Nature  1996; 382(6593): 685-91.
[http://dx.doi.org/10.1038/382685a0] [PMID:  8751438] 
[17] 
Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell  2010; 140(6): 918-34.
[http://dx.doi.org/10.1016/j.cell.2010.02.016] [PMID:  20303880] 
[18] 
Sorci G, Riuzzi F, Giambanco I, Donato R. RAGE in tissue homeostasis, repair and regeneration. Biochim Biophys Acta  2013; 1833(1): 101-9.
[http://dx.doi.org/10.1016/j.bbamcr.2012.10.021] [PMID:  23103427] 
[19] 
Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem  1992; 267(21): 14998-5004.
[http://dx.doi.org/10.1016/S0021-9258(18)42138-2] [PMID:  1378843] 
[20] 
Han SH, Kim YH, Mook-Jung I. RAGE: The beneficial and deleterious effects by diverse mechanisms of actions. Mol Cells  2011; 31(2): 91-7.
[http://dx.doi.org/10.1007/s10059-011-0030-x] [PMID:  21347704] 
[21] 
Amor S, Puentes F, Baker D, van der Valk P. Inflammation in neurodegenerative diseases. Immunology  2010; 129(2): 154-69.
[http://dx.doi.org/10.1111/j.1365-2567.2009.03225.x] [PMID:  20561356] 
[22] 
Rai V, Touré F, Chitayat S, et al. Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling. J Exp Med  2012; 209(13): 2339-50.
[http://dx.doi.org/10.1084/jem.20120873] [PMID:  23209312] 
[23] 
Kislinger T, Fu C, Huber B, et al. N(ε)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem  1999; 274(44): 31740-9.
[http://dx.doi.org/10.1074/jbc.274.44.31740] [PMID:  10531386] 
[24] 
Giri R, Shen Y, Stins M, et al. β-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am J Physiol Cell Physiol  2000; 279(6): C1772-81.
[http://dx.doi.org/10.1152/ajpcell.2000.279.6.C1772] [PMID:  11078691] 
[25] 
McManus CJ, Graveley BR. RNA structure and the mechanisms of alternative splicing. Curr Opin Genet Dev  2011; 21(4): 373-9.
[http://dx.doi.org/10.1016/j.gde.2011.04.001] [PMID:  21530232] 
[26] 
Hori O, Brett J, Slattery T, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem  1995; 270(43): 25752-61.
[http://dx.doi.org/10.1074/jbc.270.43.25752] [PMID:  7592757] 
[27] 
Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: From evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun  2004; 322(4): 1111-22.
[http://dx.doi.org/10.1016/j.bbrc.2004.07.096] [PMID:  15336958] 
[28] 
Fritz G, Botelho HM, Morozova-Roche LA, Gomes CM. Natural and amyloid self-assembly of S100 proteins: structural basis of functional diversity. FEBS J  2010; 277(22): 4578-90.
[http://dx.doi.org/10.1111/j.1742-4658.2010.07887.x] [PMID:  20977662] 
[29] 
Donato R, Cannon BR, Sorci G, et al. Functions of S100 proteins. Curr Mol Med  2013; 13(1): 24-57.
[http://dx.doi.org/10.2174/156652413804486214] [PMID:  22834835] 
[30] 
Farokhzadian J, Mangolian Shahrbabaki P, Bagheri V. S100A12-CD36 axis: A novel player in the pathogenesis of atherosclerosis? Cytokine  2019; 122154104
[http://dx.doi.org/10.1016/j.cyto.2017.07.010] [PMID:  28756107] 
[31] 
Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem  2000; 275(51): 40096-105.
[http://dx.doi.org/10.1074/jbc.M006993200] [PMID:  11007787] 
[32] 
Fuentes MK, Nigavekar SS, Arumugam T, et al. RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum  2007; 50(8): 1230-40.
[http://dx.doi.org/10.1007/s10350-006-0850-5] [PMID:  17587138] 
[33] 
Gromov LA, Syrovatskaya LP, Ovinova GV. Functional role of the neurospecific S-100 protein in the processes of memory. Neurosci Behav Physiol  1992; 22(1): 25-9.
[http://dx.doi.org/10.1007/BF01186664] [PMID:  1614614] 
[34] 
O’Dowd BS, Zhao WQ, Ng KT, Robinson SR. Chicks injected with antisera to either S-100 alpha or S-100 beta protein develop amnesia for a passive avoidance task. Neurobiol Learn Mem  1997; 67(3): 197-206.
[http://dx.doi.org/10.1006/nlme.1997.3766] [PMID:  9159758] 
[35] 
Epstein OI, Pavlov IF, Shtark MB. Improvement of memory by means of ultra-low doses of antibodies to S-100B antigen. Evid Based Complement Alternat Med  2006; 3(4): 541-5.
[http://dx.doi.org/10.1093/ecam/nel073] [PMID:  17173119] 
[36] 
Santos G, Barateiro A, Gomes CM, Brites D, Fernandes A. Impaired oligodendrogenesis and myelination by elevated S100B levels during neurodevelopment. Neuropharmacology  2018; 129: 69-83.
[http://dx.doi.org/10.1016/j.neuropharm.2017.11.002] [PMID:  29126910] 
[37] 
Esposito G, Imitola J, Lu J, et al. Genomic and functional profiling of human Down syndrome neural progenitors implicates S100B and aquaporin 4 in cell injury. Hum Mol Genet  2008; 17(3): 440-57.
[http://dx.doi.org/10.1093/hmg/ddm322] [PMID:  17984171] 
[38] 
Lu J, Esposito G, Scuderi C, et al. S100B and APP promote a gliocentric shift and impaired neurogenesis in Down syndrome neural progenitors. PLoS One  2011; 6(7)e22126
[http://dx.doi.org/10.1371/journal.pone.0022126] [PMID:  21779383] 
[39] 
Chen C, Jiang P, Xue H, et al. Role of astroglia in Down’s syndrome revealed by patient-derived human-induced pluripotent stem cells. Nat Commun  2014; 5: 4430.
[http://dx.doi.org/10.1038/ncomms5430] [PMID:  25034944] 
[40] 
Sorci G, Agneletti AL, Donato R. Effects of S100A1 and S100B on microtubule stability. An in vitro study using triton-cytoskeletons from astrocyte and myoblast cell lines. Neuroscience  2000; 99(4): 773-83.
[http://dx.doi.org/10.1016/S0306-4522(00)00238-4] [PMID:  10974440] 
[41] 
Wasik U, Schneider G, Mietelska-Porowska A, et al. Calcyclin binding protein and Siah-1 interacting protein in Alzheimer’s disease pathology: Neuronal localization and possible function. Neurobiol Aging  2013; 34(5): 1380-8.
[http://dx.doi.org/10.1016/j.neurobiolaging.2012.11.007] [PMID:  23260124] 
[42] 
Esposito G, Scuderi C, Lu J, et al. S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells. J Cell Mol Med  2008; 12(3): 914-27. [b
[http://dx.doi.org/10.1111/j.1582-4934.2008.00159.x] [PMID: 18494933] 
[43] 
Shepherd CE, Goyette J, Utter V, et al. Inflammatory S100A9 and S100A12 proteins in Alzheimer’s disease. Neurobiol Aging  2006; 27(11): 1554-63.
[http://dx.doi.org/10.1016/j.neurobiolaging.2005.09.033] [PMID:  16253391] 
[44] 
Sheng JG, Mrak RE, Griffin WS. Glial-neuronal interactions in Alzheimer disease: Progressive association of IL-1alpha+ microglia and S100beta+ astrocytes with neurofibrillary tangle stages. J Neuropathol Exp Neurol  1997; 56(3): 285-90.
[http://dx.doi.org/10.1097/00005072-199703000-00007] [PMID:  9056542] 
[45] 
Li G, Chen H, Cheng L, Zhao R, Zhao J, Xu Y. Amyloid precursor-like protein 2 C-terminal fragments upregulate S100A9 gene and protein expression in BV2 cells. Neural Regen Res  2014; 9(21): 1923-8.
[http://dx.doi.org/10.4103/1673-5374.145362] [PMID:  25558244] 
[46] 
Tian ZY, Wang CY, Wang T, Li YC, Wang ZY. Glial S100A6 Degrades beta-amyloid aggregation through targeting competition with zinc ions. Aging Dis  2019; 10(4): 756-69.
[http://dx.doi.org/10.14336/AD.2018.0912] [PMID:  31440382] 
[47] 
Roltsch E, Holcomb L, Young KA, Marks A, Zimmer DB. PSAPP mice exhibit regionally selective reductions in gliosis and plaque deposition in response to S100B ablation. J Neuroinflammation  2010; 7: 78.
[http://dx.doi.org/10.1186/1742-2094-7-78] [PMID:  21080947] 
[48] 
Afanador L, Roltsch EA, Holcomb L, et al. The Ca2+ sensor S100A1 modulates neuroinflammation, histopathology and Akt activity in the PSAPP Alzheimer’s disease mouse model. Cell Calcium  2014; 56(2): 68-80.
[http://dx.doi.org/10.1016/j.ceca.2014.05.002] [PMID:  24931125] 
[49] 
Kummer MP, Vogl T, Axt D, et al. Mrp14 deficiency ameliorates amyloid β burden by increasing microglial phagocytosis and modulation of amyloid precursor protein processing. J Neurosci  2012; 32(49): 17824-9.
[http://dx.doi.org/10.1523/JNEUROSCI.1504-12.2012] [PMID:  23223301] 
[50] 
Wang C, Iashchishyn IA, Pansieri J, et al. S100A9-Driven amyloid-neuroinflammatory cascade in traumatic brain injury as a precursor state for Alzheimer’s disease. Sci Rep  2018; 8(1): 12836.
[http://dx.doi.org/10.1038/s41598-018-31141-x] [PMID:  30150640] 
[51] 
Butterfield DA, Swomley AM, Sultana R. Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: Importance in disease pathogenesis and progression. Antioxid Redox Signal  2013; 19(8): 823-35.
[http://dx.doi.org/10.1089/ars.2012.5027] [PMID:  23249141] 
[52] 
Sturchler E, Galichet A, Weibel M, Leclerc E, Heizmann CW. Site-specific blockade of RAGE-Vd prevents amyloid-β oligomer neurotoxicity. J Neurosci  2008; 28(20): 5149-58.
[http://dx.doi.org/10.1523/JNEUROSCI.4878-07.2008] [PMID:  18480271] 
[53] 
Chaney MO, Stine WB, Kokjohn TA, et al. RAGE and amyloid beta interactions: Atomic force microscopy and molecular modeling. Biochim Biophys Acta  2005; 1741(1-2): 199-205.
[http://dx.doi.org/10.1016/j.bbadis.2005.03.014] [PMID:  15882940] 
[54] 
Krishnan S, Ravi S, Ponmalai S, Rani P. A molecular dynamics study on RAGE-Aβ42 interaction and the influence of G82S RAGE polymorphism on Aβ interaction. Int J Bioautomation  2015; 19(4): 433-46.
[55] 
Koch M, Chitayat S, Dattilo BM, et al. Structural basis for ligand recognition and activation of RAGE. Structure  2010; 18(10): 1342-52.
[http://dx.doi.org/10.1016/j.str.2010.05.017] 
[56] 
Fritz G. RAGE: A single receptor fits multiple ligands. Trends Biochem Sci  2011; 36(12): 625-32.
[http://dx.doi.org/10.1016/j.tibs.2011.08.008] [PMID:  22019011] 
[57] 
Park H, Adsit FG, Boyington JC. The 1.5 Å crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding. J Biol Chem  2010; 285(52): 40762-70.
[58] 
Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS. Calcium-dependent and independent interactions of the S100 protein family. Biochem J  2006; 396(2): 201-14.
[http://dx.doi.org/10.1042/BJ20060195] [PMID:  16683912] 
[59] 
Bierhaus A, Stern DM, Nawroth PP. RAGE in inflammation: A new therapeutic target? Curr Opin Invest Dr (London, England: 2000) 2006; 2006(11): 985-1.. 
[60] 
Clynes R, Moser B, Yan SF, Ramasamy R, Herold K, Schmidt AM. Receptor for AGE (RAGE): Weaving tangled webs within the inflammatory response. Curr Mol Med  2007; 7(8): 743-51.
[http://dx.doi.org/10.2174/156652407783220714] [PMID:  18331232] 
[61] 
Herold K, Moser B, Chen Y, et al. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: Inflammatory signals gone awry in the primal response to stress. J Leukoc Biol  2007; 82(2): 204-12.
[http://dx.doi.org/10.1189/jlb.1206751] [PMID:  17513693] 
[62] 
Collison KS, Parhar RS, Saleh SS, et al. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol  2002; 71(3): 433-44.
[PMID: 11867681] 
[63] 
Gebhardt C, Riehl A, Durchdewald M, et al. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med  2008; 205(2): 275-85.
[http://dx.doi.org/10.1084/jem.20070679] [PMID:  18208974] 
[64] 
Chen Y, Akirav EM, Chen W, et al. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol  2008; 181(6): 4272-8.
[http://dx.doi.org/10.4049/jimmunol.181.6.4272] [PMID:  18768885] 
[65] 
Chavakis T, Bierhaus A, Al-Fakhri N, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment. J Exp Med  2003; 198(10): 1507-15.
[http://dx.doi.org/10.1084/jem.20030800] [PMID:  14623906] 
[66] 
Orlova VV, Choi EY, Xie C, et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J  2007; 26(4): 1129-39.
[http://dx.doi.org/10.1038/sj.emboj.7601552] [PMID:  17268551] 
[67] 
Gebhardt C, Németh J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol  2006; 72(11): 1622-31.
[http://dx.doi.org/10.1016/j.bcp.2006.05.017] [PMID:  16846592] 
[68] 
Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: A novel group of damage-associated molecular pattern molecules. J Leukoc Biol  2007; 81(1): 28-37.
[http://dx.doi.org/10.1189/jlb.0306170] [PMID:  16943388] 
[69] 
Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev  2007; 220(1): 35-46.
[http://dx.doi.org/10.1111/j.1600-065X.2007.00574.x] [PMID:  17979838] 
[70] 
Bierhaus A, Humpert PM, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl)  2005; 83(11): 876-86.
[http://dx.doi.org/10.1007/s00109-005-0688-7] [PMID:  16133426] 
[71] 
Westerterp M, Murphy AJ, Wang M, et al. Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice. Circ Res  2013; 112(11): 1456-65.
[72] 
Daffu G, Shen X, Senatus L, et al. RAGE suppresses ABCG1-mediated macrophage cholesterol efflux in diabetes. Diabetes  2015; 64(12): 4046-60.
[http://dx.doi.org/10.2337/db15-0575] [PMID:  26253613] 
[73] 
Arancio O, Zhang HP, Chen X, et al. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J  2004; 23(20): 4096-105.
[http://dx.doi.org/10.1038/sj.emboj.7600415] [PMID:  15457210] 
[74] 
Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem  1997; 272(26): 16498-506.
[http://dx.doi.org/10.1074/jbc.272.26.16498] [PMID:  9195959] 
[75] 
Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta  2000; 1498(2-3): 99-111.
[http://dx.doi.org/10.1016/S0167-4889(00)00087-2] [PMID:  11108954] 
[76] 
Bierhaus A, Schiekofer S, Schwaninger M, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes  2001; 50(12): 2792-808.
[http://dx.doi.org/10.2337/diabetes.50.12.2792] [PMID:  11723063] 
[77] 
Sparvero LJ, Asafu-Adjei D, Kang R, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med  2009; 7(1): 17.
[http://dx.doi.org/10.1186/1479-5876-7-17] [PMID:  19292913] 
[78] 
Zlokovic B, Yamada S, Holtzman D, et al. Clearance of amyloid β-peptide from brain: Transport or metabolism? Nat Med  2000; 6: 718.
[http://dx.doi.org/10.1038/77397] 
[79] 
Herz J, Strickland DK. LRP: A multifunctional scavenger and signaling receptor. J Clin Invest  2001; 108(6): 779-84.
[http://dx.doi.org/10.1172/JCI200113992] [PMID:  11560943] 
[80] 
Go GW, Mani A. Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. Yale J Biol Med  2012; 85(1): 19-28.
[PMID: 22461740] 
[81] 
Uranga RM, Keller JN. Diet and age interactions with regards to cholesterol regulation and brain pathogenesis. Curr Gerontol Geriatr Res  2010; 2010219683
[http://dx.doi.org/10.1155/2010/219683] [PMID:  20396385] 
[82] 
Ranganathan S, Liu CX, Migliorini MM, et al. Serine and threonine phosphorylation of the low density lipoprotein receptor-related protein by protein kinase Calpha regulates endocytosis and association with adaptor molecules. J Biol Chem  2004; 279(39): 40536-.
[83] 
Li Y, van Kerkhof P, Marzolo MP, Strous GJ, Bu G. Identification of a major cyclic AMP-dependent protein kinase A phosphorylation site within the cytoplasmic tail of the low-density lipoprotein receptor-related protein: Implication for receptor-mediated endocytosis. Mol Cell Biol  2001; 21(4): 1185-95.
[http://dx.doi.org/10.1128/MCB.21.4.1185-1195.2001] [PMID:  11158305] 
[84] 
Zhao Z, Sagare AP, Ma Q, et al. Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance. Nat Neurosci  2015; 18(7): 978-87.
[http://dx.doi.org/10.1038/nn.4025] [PMID:  26005850] 
[85] 
Deane R, Wu Z, Sagare A, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron  2004; 43(3): 333-44.
[86] 
Sagare A, Deane R, Bell RD, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med  2007; 13(9): 1029-31.
[http://dx.doi.org/10.1038/nm1635] [PMID:  17694066] 
[87] 
von Arnim CA, Kinoshita A, Peltan ID, et al. The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem  2005; 280(18): 17777-85.
[http://dx.doi.org/10.1074/jbc.M414248200] [PMID:  15749709] 
[88] 
Liu Q, Zhang J, Tran H, et al. LRP1 shedding in human brain: Roles of ADAM10 and ADAM17. Mol Neurodegener  2009; 4: 17.
[http://dx.doi.org/10.1186/1750-1326-4-17] 
[89] 
Rozanov DV, Hahn-Dantona E, Strickland DK, Strongin AY. The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells. J Biol Chem  2004; 279(6): 4260-8.
[http://dx.doi.org/10.1074/jbc.M311569200] [PMID:  14645246] 
[90] 
Polavarapu R, Gongora MC, Yi H, et al. Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit. Blood  2007; 109(8): 3270-8.
[http://dx.doi.org/10.1182/blood-2006-08-043125] [PMID:  17170123] 
[91] 
Donahue JE, Flaherty SL, Johanson CE, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. Acta Neuropathol  2006; 112(4): 405-15.
[http://dx.doi.org/10.1007/s00401-006-0115-3] [PMID:  16865397] 
[92] 
Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat Med  2003; 9(7): 907-13.
[http://dx.doi.org/10.1038/nm890] [PMID:  12808450] 
[93] 
Shiiki T, Ohtsuki S, Kurihara A, et al. Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J Neurosci  2004; 24(43): 9632-7.
[94] 
Sagare AP, Bell RD, Srivastava A, et al. A lipoprotein receptor cluster IV mutant preferentially binds amyloid-β and regulates its clearance from the mouse brain. J Biol Chem  2013; 288(21): 15154-66.
[http://dx.doi.org/10.1074/jbc.M112.439570] [PMID:  23580652] 
[95] 
Sagare AP, Deane R, Zlokovic BV. Low-density lipoprotein receptor-related protein 1: A physiological Aβ homeostatic mechanism with multiple therapeutic opportunities. Pharmacol Ther  2012; 136(1): 94-105.
[http://dx.doi.org/10.1016/j.pharmthera.2012.07.008] [PMID:  22820095] 
[96] 
Lue LF, Walker DG, Brachova L, et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer’s disease: Identification of a cellular activation mechanism. Exp Neurol  2001; 171(1): 29-45.
[http://dx.doi.org/10.1006/exnr.2001.7732] [PMID:  11520119] 
[97] 
Valente T, Gella A, Fernàndez-Busquets X, Unzeta M, Durany N. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer’s disease and diabetes mellitus. Neurobiol Dis  2010; 37(1): 67-76.
[http://dx.doi.org/10.1016/j.nbd.2009.09.008] [PMID:  19778613] 
[98] 
Origlia N, Righi M, Capsoni S, et al. Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-β-mediated cortical synaptic dysfunction. J Neurosci  2008; 28(13): 3521-30.
[http://dx.doi.org/10.1523/JNEUROSCI.0204-08.2008] [PMID:  18367618] 
[99] 
Guglielmotto M, Aragno M, Tamagno E, et al. AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation. Neurobiol Aging  2012; 33(1): 196.e13-27.
[http://dx.doi.org/10.1016/j.neurobiolaging.2010.05.026] [PMID:  20638753] 
[100] 
Origlia N, Capsoni S, Cattaneo A, et al. Abeta-dependent Inhibition of LTP in different intracortical circuits of the visual cortex: The role of RAGE. J Alzheimers Dis  2009; 17(1): 59-68.
[http://dx.doi.org/10.3233/JAD-2009-1045] [PMID:  19221410] 
[101] 
Kuhla B, Loske C, Garcia De Arriba S, Schinzel R, Huber J, Münch G. Differential effects of “Advanced glycation endproducts” and β-amyloid peptide on glucose utilization and ATP levels in the neuronal cell line SH-SY5Y. J Neural Transm (Vienna)  2004; 111(3): 427-39.
[http://dx.doi.org/10.1007/s00702-003-0038-2] [PMID:  14991463] 
[102] 
Takuma K, Fang F, Zhang W, et al. RAGE-mediated signaling contributes to intraneuronal transport of amyloid-β and neuronal dysfunction. Proc Natl Acad Sci USA  2009; 106(47): 20021-6.
[http://dx.doi.org/10.1073/pnas.0905686106] [PMID:  19901339] 
[103] 
Castelli V, Benedetti E, Antonosante A, et al. Neuronal cells rearrangement during aging and neurodegenerative disease: Metabolism, oxidative stress and organelles dynamic. Front Mol Neurosci  2019; 12: 132.
[104] 
Perrone L, Sbai O, Nawroth PP, Bierhaus A. The complexity of sporadic Alzheimer’s disease pathogenesis: The role of RAGE as therapeutic target to promote neuroprotection by inhibiting neurovascular dysfunction. Int J Alzheimers Dis  2012; 2012734956
[http://dx.doi.org/10.1155/2012/734956] [PMID:  22482078] 
[105] 
Fuller S, Steele M, Münch G. Activated astroglia during chronic inflammation in Alzheimer’s disease--do they neglect their neurosupportive roles? Mutat Res  2010; 690(1-2): 40-9.
[http://dx.doi.org/10.1016/j.mrfmmm.2009.08.016] [PMID:  19748514] 
[106] 
Fang F, Lue LF, Yan S, et al. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer’s disease. FASEB J  2010; 24(4): 1043-55.
[http://dx.doi.org/10.1096/fj.09-139634] [PMID:  19906677] 
[107] 
Mackic JB, Bading J, Ghiso J, et al. Circulating amyloid-β peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer’s disease lesions. Vascul Pharmacol  2002; 38(6): 303-13.
[http://dx.doi.org/10.1016/S1537-1891(02)00198-2] [PMID:  12529925] 
[108] 
Martel CL, Mackic JB, McComb JG, Ghiso J, Zlokovic BV. Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer’s amyloid β in guinea pigs. Neurosci Lett  1996; 206(2-3): 157-60.
[http://dx.doi.org/10.1016/S0304-3940(96)12462-9] [PMID:  8710175] 
[109] 
Malm T, Koistinaho M, Muona A, Magga J, Koistinaho J. The role and therapeutic potential of monocytic cells in Alzheimer’s disease. Glia  2010; 58(8): 889-900.
[http://dx.doi.org/10.1002/glia.20973] [PMID:  20155817] 
[110] 
Giri R, Selvaraj S, Miller CA, et al. Effect of endothelial cell polarity on β-amyloid-induced migration of monocytes across normal and AD endothelium. Am J Physiol Cell Physiol  2002; 283(3): C895-904.
[http://dx.doi.org/10.1152/ajpcell.00293.2001] [PMID:  12176746] 
[111] 
Gospodarska E, Kupniewska-Kozak A, Goch G, Dadlez M. Binding studies of truncated variants of the Aβ peptide to the V-domain of the RAGE receptor reveal Aβ residues responsible for binding. Biochim Biophys Acta  2011; 1814(5): 592-609.
[http://dx.doi.org/10.1016/j.bbapap.2011.02.011] [PMID:  21354340] 
[112] 
Krishnan S, Rani P. Polymorphism in the ligand binding domain of rage alters its binding affinity towards Aβ42 peptides: An in-silico study. IJBRA  2016; 12(3): 181-93.
[http://dx.doi.org/10.1504/IJBRA.2016.078226] 
[113] 
Baiguera S, Fioravanzo L, Grandi C, Di Liddo R, Parnigotto PP, Folin M. Involvement of the receptor for advanced glycation-end products (RAGE) in β-amyloid-induced toxic effects in rat cerebromicrovascular endothelial cells cultured in vitro. Int J Mol Med  2009; 24(1): 9-15.
[PMID: 19513528] 
[114] 
Falcone C, Emanuele E, D’Angelo A, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol  2005; 25(5): 1032-7.
[http://dx.doi.org/10.1161/01.ATV.0000160342.20342.00] [PMID:  15731496] 
[115] 
Quade-Lyssy P, Kanarek AM, Baiersdörfer M, Postina R, Kojro E. Statins stimulate the production of a soluble form of the receptor for advanced glycation end products. J Lipid Res  2013; 54(11): 3052-61.
[http://dx.doi.org/10.1194/jlr.M038968] [PMID:  23966666] 
[116] 
Lee EJ, Park EY, Mun H, et al. Soluble receptor for advanced glycation end products inhibits disease progression in autosomal dominant polycystic kidney disease by down-regulating cell proliferation. FASEB J  2015; 29(8): 3506-14.
[http://dx.doi.org/10.1096/fj.15-272302] [PMID:  25934702] 
[117] 
Qi XM, Ma JF. The role of amyloid beta clearance in cerebral amyloid angiopathy: More potential therapeutic targets. Transl Neurodegener  2017; 6(1): 22.
[http://dx.doi.org/10.1186/s40035-017-0091-7] [PMID:  28824801] 
[118] 
Kuhla B, Boeck K, Schmidt A, et al. Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer’s disease brains. Neurobiol Aging  2007; 28(1): 29-41.
[http://dx.doi.org/10.1016/j.neurobiolaging.2005.11.007] [PMID:  16427160] 
[119] 
More SS, Vartak AP, Vince R. Restoration of glyoxalase enzyme activity precludes cognitive dysfunction in a mouse model of Alzheimer’s disease. ACS Chem Neurosci  2013; 4(2): 330-8.
[http://dx.doi.org/10.1021/cn3001679] [PMID:  23421684] 
[120] 
Chellappa RC, Rani P. G82S RAGE polymorphism is associated with Alzheimer’s disease. Front Biosci (Elite Ed)  2020; 12: 150-61.
[http://dx.doi.org/10.2741/e864] [PMID:  32114455] 
[121] 
Bermejo P, Martín-Aragón S, Benedí J, et al. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer’s disease. Immunol Lett  2008; 117(2): 198-202.
[http://dx.doi.org/10.1016/j.imlet.2008.02.002] [PMID:  18367253] 
[122] 
Di Filippo M, Tozzi A, Costa C, et al. Plasticity and repair in the post-ischemic brain. Neuropharmacology  2008; 55(3): 353-62.
[http://dx.doi.org/10.1016/j.neuropharm.2008.01.012] [PMID:  18359495] 
[123] 
Kong Y, Wang F, Wang J, et al. Pathological mechanisms linking diabetes mellitus and alzheimer’s disease: The receptor for advanced glycation end products (RAGE). Front Aging Neurosci  2020; 12: 217.
[124] 
Wang P, Huang R, Lu S, et al. RAGE and AGEs in mild cognitive impairment of diabetic patients: A cross-sectional study. PLoS One  2006; 11(1)e0145521
[125] 
West RK, Moshier E, Lubitz I, et al. Dietary advanced glycation end products are associated with decline in memory in young elderly. Mech Ageing Dev  2014; 140: 10-2.
[http://dx.doi.org/10.1016/j.mad.2014.07.001] [PMID:  25037023] 
[126] 
Cai W, Uribarri J, Zhu L, et al. Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc Natl Acad Sci USA  2014; 111(13): 4940-5.
[http://dx.doi.org/10.1073/pnas.1316013111] 
[127] 
Bongarzone S, Savickas V, Luzi F, Gee AD. Targeting the receptor for advanced glycation endproducts (RAGE): A medicinal chemistry perspective. J Med Chem  2017; 60(17): 7213-32.
[http://dx.doi.org/10.1021/acs.jmedchem.7b00058] [PMID:  28482155] 
[128] 
Oh S, Son M, Choi J, Lee S, Byun K. sRAGE prolonged stem cell survival and suppressed RAGE-related inflammatory cell and T lymphocyte accumulations in an Alzheimer’s disease model. Biochem Biophys Res Commun  2018; 495(1): 807-13.
[129] 
Hu Q, Yu B, Chen Q, et al. Effect of Linguizhugan decoction on neuroinflammation and expression disorder of the amyloid β related transporters RAGE and LRP 1 in a rat model of Alzheimer’s disease. Mol Med Rep  2018; 17(1): 827-34.
[PMID: 29115637] 
[130] 
Deane R, Singh I, Sagare AP, et al. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest  2012; 122(4): 1377-92.
[http://dx.doi.org/10.1172/JCI58642] [PMID:  22406537] 
[131] 
Cirillo C, Capoccia E, Iuvone T, et al. S100B inhibitor pentamidine attenuates reactive gliosis and reduces neuronal loss in a mouse model of Alzheimer’s disease. BioMed Res Int  2015; 2015508342
[http://dx.doi.org/10.1155/2015/508342] [PMID:  26295040] 
[132] 
Cui L, Cai Y, Cheng W, et al. A novel, multi-target natural drug candidate, Matrine, improves cognitive deficits in Alzheimer’s disease transgenic mice by inhibiting Aβ aggregation and blocking the RAGE/Aβ Axis. Mol Neurobiol  2017; 54(3): 1939-52.
[http://dx.doi.org/10.1007/s12035-016-9783-8] [PMID:  26899576] 
[133] 
Hong Y, An Z. Hesperidin attenuates learning and memory deficits in APP/PS1 mice through activation of Akt/Nrf2 signaling and inhibition of RAGE/NF-κB signaling. Arch Pharm Res  2018; 41(6): 655-63.
[http://dx.doi.org/10.1007/s12272-015-0662-z] [PMID:  26391026] 
[134] 
Burstein AH, Sabbagh M, Andrews R, Valcarce C, Dunn I, Altstiel L. Development of Azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer’s disease. J Prev Alzheimers Dis  2018; 5(2): 149-54.
[PMID:  29616709] 
[135] 
Deane RJ. Is RAGE still a therapeutic target for Alzheimer’s disease? Future Med Chem  2012; 4(7): 915-25.
[http://dx.doi.org/10.4155/fmc.12.51] [PMID:  22571615] 
[136] 
ClinicalTrials.gov; Bethesda (MD): National Library of Medicine	(US). Identifier NCT00566397, A Phase 2 Study Evaluating The	Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's	Disease 2007. Available from:. https://clinicaltrials.gov/ct2/show/results/NCT00566397
[137] 
 ClinicalTrials.gov; Bethesda (MD): National Library of Medicin	(US). Identifier NCT02916056, 2-year extension study of azeliragon	in subjects with Alzheimer's disease (STEADFAST Extension)	2016. Available from; https://clinicaltrials.gov/ct2/show/NCT02916056. 
[138] 
] ClinicalTrials.gov; Bethesda (MD): National Library of Medicine	(US). Identifier NCT02080364, Evaluation of the Efficacy and	Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's	Disease (STEADFAST) 2015. Available from: . https://clinicaltrials. gov/ct2/show/NCT02080364
[139] 
ClinicalTrials.gov; Bethesda (MD): National Library of Medicine	(US). Identifier NCT03980730, Study of Azeliragon in Patients	With Mild Alzheimer's Disease and Impaired Glucose Tolerance	(Elevage) 2019. Available from: . https://clinicaltrials.gov/ct2/show/NCT03980730
[140] 
Galasko D, Bell J, Mancuso JY, et al. Alzheimer’s Disease Cooperative, S. Clinical trial of an inhibitor of RAGE-Abeta interactions in Alzheimer disease. Neurology  2014; 82: 1536-42.
[http://dx.doi.org/10.1212/WNL.0000000000000364] [PMID:  24696507] 
Rights & Permissions Print Cite
Article Metrics
30
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1567205018666210218164246	Print ISSN 1567-2050
Publisher Name Bentham Science Publisher	Online ISSN 1875-5828
当代阿耳茨海默病研究

RAGE异体及其配体及其在阿尔茨海默病病理生理学中的作用

摘要

当代阿耳茨海默病研究

RAGE异体及其配体及其在阿尔茨海默病病理生理学中的作用

摘要 Play Pause

Related Journals

Related Books

Related Articles

摘要
